⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28159045 | 0.79 | — | — | |
| SCHEMBL16297573 | 0.78 | — | — | |
| SCHEMBL2441790 | 0.78 | — | — | |
| SCHEMBL1966551 | 0.78 | LMNA (0.41) | — | |
| SCHEMBL19741477 | 0.76 | ALDH1A1 (0.38) | — | |
| SCHEMBL159060 | 0.76 | — | — | |
| SCHEMBL3850484 | 0.76 | — | — | |
| SCHEMBL10566117 | 0.76 | — | — | |
| SCHEMBL7753360 | 0.76 | TSHR (0.43) | — | |
| SCHEMBL293753 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1654268-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1121369-B1 | RIBAVIRIN-INTERFERON ALFA COMBINATION THERAPY FOR ERADICATING DETECTABLE HCV-RNA IN PATIENTS HAVING CHRONIC HEPATITIS C INFECTION | SCHERING CORP (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1282632-A1 | RIBAVIRIN-INTERFERON ALFA COMBINATION THERAPY FOR ERADICATING DETECTABLE HCV-RNA IN PATIENTS HAVING CHRONIC HEPATITIS C INFECTION | SCHERING CORPORATION (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001081359-A1 | RIBAVIRIN-INTERFERON ALFA COMBINATION THERAPY FOR ERADICATING DETECTABLE HCV-RNA IN PATIENTS HAVING CHRONIC HEPATITIS C INFECTION | SCHERING CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| CN-1143960-A | Therapeutic heterocyclic compounds | WELLCOME FOUND (GB) | 1997-02-26 | — | — | CN | disclosed |